Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 375

1.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N.

Eur Urol. 2013 Feb;63(2):296-305. doi: 10.1016/j.eururo.2012.10.048.

PMID:
23195283
2.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C.

Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016.

PMID:
23182126
3.

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.

Chapple CR, Kaplan SA, Mitcheson D, Blauwet MB, Huang M, Siddiqui E, Khullar V.

Int J Urol. 2014 Oct;21(10):960-7. doi: 10.1111/iju.12568.

4.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, Martin N, Gunther A, Van Kerrebroeck P.

Urology. 2013 Aug;82(2):313-20. doi: 10.1016/j.urology.2013.02.077. Erratum in: Urology. 2013 Dec;82(6):1457.

PMID:
23769122
5.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

6.

Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.

Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012.

PMID:
24612659
7.

Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.

Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Ikeda Y, Ohkawa S.

BJU Int. 2014 Jun;113(6):951-60. doi: 10.1111/bju.12649.

8.

Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.

Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K.

Neurourol Urodyn. 2015 Sep;34(7):685-92. doi: 10.1002/nau.22645.

PMID:
25130281
9.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

10.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252.

PMID:
22907761
11.

Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.

Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC.

Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Review.

PMID:
24127366
12.

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z.

JAMA. 2006 Nov 15;296(19):2319-28. Erratum in: JAMA. 2007 Mar 21:297(11):1195. JAMA. 2007 Oct 24;298(16):1864.

PMID:
17105794
13.
14.
15.

Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.

Chapple C, Khullar V, Nitti VW, Frankel J, Herschorn S, Kaper M, Blauwet MB, Siddiqui E.

Eur Urol. 2015 Jan;67(1):11-4. doi: 10.1016/j.eururo.2014.06.052.

PMID:
25092537
16.

Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.

Gacci M, Novara G, De Nunzio C, Tubaro A, Schiavina R, Brunocilla E, Sebastianelli A, Salvi M, Oelke M, Gravas S, Carini M, Serni S.

BMC Urol. 2014 Oct 27;14:84. doi: 10.1186/1471-2490-14-84. Review.

17.

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.

Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.

Eur Urol. 2009 Sep;56(3):534-41. doi: 10.1016/j.eururo.2008.11.026.

PMID:
19070418
18.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
19.

Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.

Pavesi M, Devlin N, Hakimi Z, Nazir J, Herdman M, Hoyle C, Odeyemi IA.

J Med Econ. 2013 Jul;16(7):866-76. doi: 10.3111/13696998.2013.802240.

PMID:
23647446
20.

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE.

Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194.

Items per page

Supplemental Content

Support Center